In this study, we functionally dissected tumor-intrinsic mechanisms of immunotherapy resistance in a unique panel of short-term melanoma cell lines, termed PD1 PROGs, and matched tumor biopsies derived from 18 patients progressing on PD1 inhibitors, either alone or in combination with ipilimumab. This evidence concerns the gene PDCD1 and neoplasm.